Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03541863

YOUNGBC-1

Details and patient eligibility

About

What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.

Full description

There is no evidence of treatment after progression of Ful. We retrospectively evaluated HR+, HER2- MBC patients failed on Ful 500mg as first line or second line therapy from 2014 to 2017 in 6 institutions. Treatment pattern, PFS, OS and safety were analyzed to figure out the situation and efficacy of treatment after Fulvestrant.

Enrollment: 131 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were treated with Fulvestrant between June 2014 to June 2017 as first line or second line therapy
• Patients received subsequent treatment after progressing on Fulvestrant for at least one cycle (>1 month)
• Complete medical history was available

Exclusion criteria

• Subsequent treatment was not standard therapy (cannot be classified into endocrine therapy/ chemotherapy)
• Medical history was incomplete

Trial design

131 participants in 2 patient groups

Endocrine therapy

Description:

use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus

Chemotherapy

Description:

use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based